213 related articles for article (PubMed ID: 38377196)
41. KRAS Inhibitors- yes but what next? Direct targeting of KRAS- vaccines, adoptive T cell therapy and beyond.
Nagasaka M; Potugari B; Nguyen A; Sukari A; Azmi AS; Ou SI
Cancer Treat Rev; 2021 Dec; 101():102309. PubMed ID: 34715449
[TBL] [Abstract][Full Text] [Related]
42. Novel approaches for the development of direct KRAS inhibitors: structural insights and drug design.
Haider K; Sharma A; Yar MS; Yakkala PA; Shafi S; Kamal A
Expert Opin Drug Discov; 2022 Mar; 17(3):247-257. PubMed ID: 35084268
[TBL] [Abstract][Full Text] [Related]
43. Profiling oncogenic KRAS mutant drugs with a cell-based Lumit p-ERK immunoassay.
Swiatnicki M; Engel L; Shrestha R; Alves J; Goueli SA; Zegzouti H
SLAS Discov; 2022 Jun; 27(4):249-257. PubMed ID: 35288294
[TBL] [Abstract][Full Text] [Related]
44. [Current status and outlook of medical treatment for
Xu W; Zhuo XL; Liu L; Zhao J; Lin XY; Fu GB
Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):111-116. PubMed ID: 36781231
[TBL] [Abstract][Full Text] [Related]
45. Ganoderma microsporum immunomodulatory protein combined with KRAS
Hua WJ; Hwang WL; Yeh H; Lin ZH; Hsu WH; Lin TY
Int J Biol Macromol; 2024 Feb; 259(Pt 2):129291. PubMed ID: 38211909
[TBL] [Abstract][Full Text] [Related]
46. Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review).
Zhang J; Darman L; Hassan MS; Von Holzen U; Awasthi N
Oncol Rep; 2023 Nov; 50(5):. PubMed ID: 37800636
[TBL] [Abstract][Full Text] [Related]
47. Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C-Mutant Non-Small Cell Lung Cancer.
Adachi Y; Ito K; Hayashi Y; Kimura R; Tan TZ; Yamaguchi R; Ebi H
Clin Cancer Res; 2020 Nov; 26(22):5962-5973. PubMed ID: 32900796
[TBL] [Abstract][Full Text] [Related]
48. KRAS: A Druggable Target in Colon Cancer Patients.
Negri F; Bottarelli L; de'Angelis GL; Gnetti L
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456940
[TBL] [Abstract][Full Text] [Related]
49. Facts and Hopes on RAS Inhibitors and Cancer Immunotherapy.
Boumelha J; Molina-Arcas M; Downward J
Clin Cancer Res; 2023 Dec; 29(24):5012-5020. PubMed ID: 37581538
[TBL] [Abstract][Full Text] [Related]
50. KRAS G12C NSCLC Models Are Sensitive to Direct Targeting of KRAS in Combination with PI3K Inhibition.
Misale S; Fatherree JP; Cortez E; Li C; Bilton S; Timonina D; Myers DT; Lee D; Gomez-Caraballo M; Greenberg M; Nangia V; Greninger P; Egan RK; McClanaghan J; Stein GT; Murchie E; Zarrinkar PP; Janes MR; Li LS; Liu Y; Hata AN; Benes CH
Clin Cancer Res; 2019 Jan; 25(2):796-807. PubMed ID: 30327306
[TBL] [Abstract][Full Text] [Related]
51. KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges.
Moldvay J; Tímár J
Pathol Oncol Res; 2023; 29():1611580. PubMed ID: 38239281
[TBL] [Abstract][Full Text] [Related]
52. FDA Approval Summary: Sotorasib for KRAS G12C-Mutated Metastatic NSCLC.
Nakajima EC; Drezner N; Li X; Mishra-Kalyani PS; Liu Y; Zhao H; Bi Y; Liu J; Rahman A; Wearne E; Ojofeitimi I; Hotaki LT; Spillman D; Pazdur R; Beaver JA; Singh H
Clin Cancer Res; 2022 Apr; 28(8):1482-1486. PubMed ID: 34903582
[TBL] [Abstract][Full Text] [Related]
53. EGFR Blockade Reverts Resistance to KRAS
Amodio V; Yaeger R; Arcella P; Cancelliere C; Lamba S; Lorenzato A; Arena S; Montone M; Mussolin B; Bian Y; Whaley A; Pinnelli M; Murciano-Goroff YR; Vakiani E; Valeri N; Liao WL; Bhalkikar A; Thyparambil S; Zhao HY; de Stanchina E; Marsoni S; Siena S; Bertotti A; Trusolino L; Li BT; Rosen N; Di Nicolantonio F; Bardelli A; Misale S
Cancer Discov; 2020 Aug; 10(8):1129-1139. PubMed ID: 32430388
[TBL] [Abstract][Full Text] [Related]
54. Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas.
Salmón M; Álvarez-Díaz R; Fustero-Torre C; Brehey O; Lechuga CG; Sanclemente M; Fernández-García F; López-García A; Martín-Guijarro MC; Rodríguez-Perales S; Bousquet-Mur E; Morales-Cacho L; Mulero F; Al-Shahrour F; Martínez L; Domínguez O; Caleiras E; Ortega S; Guerra C; Musteanu M; Drosten M; Barbacid M
J Clin Invest; 2023 Apr; 133(7):. PubMed ID: 36928090
[TBL] [Abstract][Full Text] [Related]
55. A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer.
Iams WT; Balbach ML; Phillips S; Sacher A; Bestvina C; Velcheti V; Wang X; Marmarelis ME; Sethakorn N; Leal T; Sackstein PE; Kim C; Robinson MA; Mehta K; Hsu R; Nieva J; Patil T; Camidge DR
Clin Lung Cancer; 2023 May; 24(3):228-234. PubMed ID: 36841727
[TBL] [Abstract][Full Text] [Related]
56. KRAS mutation: from undruggable to druggable in cancer.
Huang L; Guo Z; Wang F; Fu L
Signal Transduct Target Ther; 2021 Nov; 6(1):386. PubMed ID: 34776511
[TBL] [Abstract][Full Text] [Related]
57. KRAS
Hong DS; Fakih MG; Strickler JH; Desai J; Durm GA; Shapiro GI; Falchook GS; Price TJ; Sacher A; Denlinger CS; Bang YJ; Dy GK; Krauss JC; Kuboki Y; Kuo JC; Coveler AL; Park K; Kim TW; Barlesi F; Munster PN; Ramalingam SS; Burns TF; Meric-Bernstam F; Henary H; Ngang J; Ngarmchamnanrith G; Kim J; Houk BE; Canon J; Lipford JR; Friberg G; Lito P; Govindan R; Li BT
N Engl J Med; 2020 Sep; 383(13):1207-1217. PubMed ID: 32955176
[TBL] [Abstract][Full Text] [Related]
58. KRAS
Ryan MB; Coker O; Sorokin A; Fella K; Barnes H; Wong E; Kanikarla P; Gao F; Zhang Y; Zhou L; Kopetz S; Corcoran RB
Cell Rep; 2022 Jun; 39(12):110993. PubMed ID: 35732135
[TBL] [Abstract][Full Text] [Related]
59. Landscape of
Salem ME; El-Refai SM; Sha W; Puccini A; Grothey A; George TJ; Hwang JJ; O'Neil B; Barrett AS; Kadakia KC; Musselwhite LW; Raghavan D; Van Cutsem E; Tabernero J; Tie J
JCO Precis Oncol; 2022 Mar; 6():e2100245. PubMed ID: 35319967
[TBL] [Abstract][Full Text] [Related]
60.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
